- Home
- VOYA vs MDGL Comparison
VOYA vs MDGL Comparison
Compare VOYA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOYA
- MDGL
- Stock Information
- Founded
- VOYA 1975
- MDGL 2011
- Country
- VOYA United States
- MDGL United States
- Employees
- VOYA N/A
- MDGL N/A
- Industry
- VOYA Life Insurance
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- VOYA Finance
- MDGL Health Care
- Exchange
- VOYA Nasdaq
- MDGL Nasdaq
- Market Cap
- VOYA 6.8B
- MDGL 7.5B
- IPO Year
- VOYA 2013
- MDGL N/A
- Fundamental
- Price
- VOYA $67.80
- MDGL $331.23
- Analyst Decision
- VOYA Buy
- MDGL Buy
- Analyst Count
- VOYA 13
- MDGL 10
- Target Price
- VOYA $81.92
- MDGL $354.75
- AVG Volume (30 Days)
- VOYA 1.1M
- MDGL 338.0K
- Earning Date
- VOYA 04-29-2025
- MDGL 05-06-2025
- Dividend Yield
- VOYA 2.64%
- MDGL N/A
- EPS Growth
- VOYA 13.84
- MDGL N/A
- EPS
- VOYA 6.17
- MDGL N/A
- Revenue
- VOYA $8,050,000,000.00
- MDGL $180,133,000.00
- Revenue This Year
- VOYA N/A
- MDGL $217.05
- Revenue Next Year
- VOYA $5.47
- MDGL $84.73
- P/E Ratio
- VOYA $11.05
- MDGL N/A
- Revenue Growth
- VOYA 9.55
- MDGL N/A
- 52 Week Low
- VOYA $64.10
- MDGL $189.00
- 52 Week High
- VOYA $84.30
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- VOYA 44.39
- MDGL 48.41
- Support Level
- VOYA $66.29
- MDGL $330.73
- Resistance Level
- VOYA $71.15
- MDGL $350.50
- Average True Range (ATR)
- VOYA 1.54
- MDGL 13.55
- MACD
- VOYA 0.12
- MDGL -1.15
- Stochastic Oscillator
- VOYA 47.33
- MDGL 52.42
About VOYA Voya Financial Inc.
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.